HOME >> BIOLOGY >> NEWS
First gene therapy to calm pigs' out-of-sync hearts

"The number one killer in developed countries is cardiac death, generally sparked by an event that leads to arrhythmia."

Scientists at Johns Hopkins have developed a gene therapy that, within a week, quells abnormal rhythms in pig hearts, the animal hearts most similar to human. It's believed to be the first use of gene therapy for cardiac arrhythmias, the researchers say, and one with "a strong possibility" of transfer to human heart disease.

"We've effectively treated an arrythmia in a well-tested animal model, using genes delivered by routine catheter methods no open chest, no contrivances, just simple modifications of existing technology," says Eduardo Marban, M.D., Ph.D., one of the scientists.

"This is the first proof-of-concept work," says Marban, "and the first clear step toward a clinically useful approach."

A report of the research appears in the December issue of the journal Nature Medicine.

Arrhythmias arise from two sources, the researchers say. One is a basic structural abnormality in the heart's pacemakers. The other develops after a heart attack or other insult to the heart. "Shortly after such an event," says team leader Kevin Donahue, M.D., "cellular changes, such as scarring, take place in the heart and make tissue more prone to arrhythmias. The number one killer in developed countries is cardiac death, generally sparked by an event that leads to arrhythmia."

Approximately one in every hundred people in this country suffers from arrythmias of one sort or another, according to the American Heart Association. While some heart rhythm disturbances are relatively benign, others, by disrupting the heart's coordinated pumping, are an immediate cause of collapse and death.

"Drug treatments can help, but don't fix the underlying causes of the problem," Donahue adds, "and continued use can actually encourage arrhythmias in some people. Pacemakers or defibrillators are expensive and
'"/>

Contact: Marjorie Centofanti
mcentofanti@jhmi.edu
410-955-8725
Johns Hopkins Medical Institutions
30-Nov-2000


Page: 1 2 3

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
10. First flavors form a lasting impression
11. STN International launches Derwent World Patents Index First View

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , a ... for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology Association ... of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 single ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global leader ... Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan. ... in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply ...
(Date:6/28/2020)... (PRWEB) , ... June 25, ... ... of enterprise software solutions for biopharmaceutical R&D, today announced that it has ... developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... 08, 2020 , ... Bode Technology, a leading ... operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical ... provides a turnkey solution that includes a comprehensive collection and virus-management program ...
(Date:7/10/2020)... ... 09, 2020 , ... In most research using the zebrafish ... formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging. Over the ... using the zebrafish model to investigate the causes of leukaemia and its relationship ...
(Date:7/7/2020)... ... , ... R3 International is now offering stem cell therapy for Alzheimers dementia ... on the patient's condition, treatment may be offered IV, intrathecal or with a combination. ... Alzheimers dementia, and the incidence continues to increase as individuals live longer. There is ...
(Date:7/1/2020)... CHARLOTTE, N.C. (PRWEB) , ... June 29, 2020 ... ... has reported year to date growth of 40% in 2020, despite many obstacles ... medical technology, MedShift aims to increase revenue for its partnered medical practices and ...
Breaking Biology Technology:
Cached News: